Workshop 02 - Radiopharmaceutical Therapy Workshop

Moderator(s)

• 

  Jacqueline Zoberi, PhD

  Washington University School of Medicine in St. Louis
  St. Louis, MO
• 

  Bridget Koontz, MD, FASTRO

  AdventHealth Cancer Institute
  Durham, NC
• RS

  Richard Stock, MD

  Mount Sinai School of Medicine
  New York, NY

Radiopharmaceuticals are an increasingly utilized therapeutic option for the treatment of malignancies. This session will focus on clinical indications, difficult cases, medical physics considerations, development of standard operating procedures for clinical implementation, billing and safe theranostic delivery practices. Specifically, Radium-223, Lutetium-177 dotatate and Lutetium-177 PSMA-617 will be discussed. The session will include didactic presentation from physician experts from radiation oncology, nuclear medicine, medical oncology and medical physicists, with question and answer sessions to discuss practice implementation in various clinical settings (i.e., academic hospital vs. community practice, nuclear medicine vs. radiation oncology). The purpose of the Master Class is to increase physician, physicist, billing and administration understanding on how to effectively and safely develop a radiopharmaceutical program at their respective institutions.

Presentations:

• 1:00 PM – 1:05 PM ET

  Introductions
  

  Speaker: Jacqueline Zoberi, PhD – Washington University School of Medicine in St. Louis
• 1:05 PM – 1:35 PM ET

  Introduction to Radiopharmaceutical Therapy & Basics of Radiobiology
  

  Speaker: Ana Kiess, MD, PhD – Johns Hopkins University
• 1:35 PM – 2:00 PM ET

  Basics of Physics for Radiopharmaceutical Therapies - with a Focus on Dosimetry
  

  Speaker: Stephen Graves, PhD – University of Iowa
• 2:00 PM – 2:20 PM ET

  Moving RPT into the Mainstream of RO and Navigating the Collaboration with NM
  

  Speaker: Hyun Kim, MD – Washington University School of Medicine in St. Louis
• 2:20 PM – 2:40 PM ET

  Enhancing Educational Opportunities in RPT for Practitioners and Trainees
  

  Speaker: Neil Taunk, MD, MS – University of Pennsylvania
• 2:40 PM – 3:05 PM ET

  Developing Standard Operating Procedures for Radiopharmaceutical Therapies
  

  Speaker: Jacqueline Zoberi, PhD – Washington University School of Medicine in St. Louis
• 3:15 PM – 3:35 PM ET

  Incorporating PSMA PET Imaging and Lu177 PSMA Therapy into Clinical Practice
  

  Speaker: Bridget Koontz, MD, FASTRO – AdventHealth Cancer Institute
• 3:35 PM – 3:55 PM ET

  The Treatment Landscape for Metastatic Prostate Cancer: Indications and Patient Selection for Lu177 PSMA Therapy vs Other Systemic Treatments
  

  Speaker: William Oh, MD – Mount Sinai Health System
• 3:55 PM – 4:05 PM ET

  What is the role of RA-223 in 2024?
  

  Speaker: Richard Stock, MD – Mount Sinai School of Medicine
• 4:05 PM – 4:30 PM ET

  Lu-177-Dotatate (NET) Clinical Indications and Community Perspective
  

  Speaker: Ravi Shridhar, MD, PhD – AdventHealth Cancer Institute
• 4:30 PM – 4:45 PM ET

  The Role of Y90 in the Treatment of Liver Cancer
  

  Speaker: Salma Jabbour, MD, FASTRO – Rutgers University
• 4:45 PM – 5:05 PM ET

  New Isotopes and Indications for RPT
  

  Speaker: Michael Folkert, MD, PhD – University of Washington-Fred Hutchinson Cancer Center
• 5:05 PM – 5:25 PM ET

  Case Presentation and Discussion
  

  Speaker: Richard Stock, MD – Mount Sinai School of Medicine
• 5:25 PM – 5:30 PM ET

  Wrap-Up
  

  Speaker: Richard Stock, MD – Mount Sinai School of Medicine